We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Revolution Medicines, Inc.는 임상 단계의 정밀 종양학 기업으로, RAS 의존성 암을 위한 신규 표적 치료제를 개발합니다. 이 회사의 연구 개발 파이프라인은 RAS 변이체에 결합하여 단독 요법으로 사용되거나, 다른 RAS(ON) 억제제, RAS 동반 억제제 또는 기타 치료제와 병용하여 사용되는 RAS(ON) 억제제와, RAS 의존성 암을 유지하는 협력 표적 및 경로를 억제하는 RAS 동반 억제제로 구성되어 있습니다. 이 회사의 RAS(ON) 억제제로는 daraxonrasib (RMC-6236), 고형암 치료를 위한 초기 임상 개발 단계